Galderma wins European approval for bone-mimicking chin filler Restylane Shaype

Galderma secured European Union approval for Restylane Shaype on August 11, 2026, giving European injectors a dedicated hyaluronic acid option specifically engineered to mimic bone for temporary chin augmentation. The product utilizes new NASHA HD technology to achieve the highest level of firmness in the Restylane range, allowing clinicians to inject deeply to shape and build directly on bone.

Data from a 12-month pivotal study shows that 83% of treated individuals had improved structure and definition at three months, with 66% maintaining those improvements at one year. Patient satisfaction was high, with 84% of patients agreeing to be treated again and up to 97% willing to recommend the treatment to a friend.

This addresses a substantial patient demand, given that roughly one-third of consumers identify issues with their chin shape and one in four worry about lower face sagging. To support clinical outcomes, Galderma is pairing the product with its structured Shayping Technique, utilizing the brand's established Assessment, Anatomy, Range, and Treatment (AART) methodology. For clinics, this provides a highly stable, firm option to capture patients seeking significant lower-face structural definition without surgery.

Source: Business Wire, https://www.businesswire.com/news/home/20260810880899/en/Galderma-Receives-European-Union-Approval-for-Restylane%C2%AE-Shaype%E2%84%A2-the-First-and-Only-Bone-Mimicking-Hyaluronic-Acid-Injectable-for-Facial-Shaping